• STAAR Surgical is trading at $27.35 (5.6% down) in pre-market, primarily driven by a negative market reaction to its strong preliminary Q2 2026 net sales report released yesterday.
  • The company announced preliminary Q2 2026 net sales are expected to exceed $90 million, a significant increase from the prior year.
  • The decline follows an after-hours dip post-announcement, influenced by factors such as a low single-digit percentage decline in EMEA region net sales due to Middle East turmoil and ongoing operational challenges related to an ERP system implementation.
  • This market sentiment also reflects broader geopolitical disruptions and macroeconomic pressures, contributing to extended volatility.